XENIA PHARMA ApS

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
Estimate generation in progress, please wait...
 
Loading...

Loading...

Loading...

Loading...

 
Loading...

Bankruptcy Risk 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  5.0% 5.7% 9.7% 11.4% 9.1%  
Credit score (0-100)  45 40 24 20 21  
Credit rating  BB BB B B B  
Credit limit (kDKK)  -0.0 -0.0 -0.0 -0.0 -0.0  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  0 0 0 0 0  
Gross profit  -3.4 -2.2 -27.5 -53.7 -18.9  
EBITDA  -3.4 -2.2 -27.5 -53.7 -18.9  
EBIT  -3.4 -2.2 -27.5 -53.7 -18.9  
Pre-tax profit (PTP)  -3.4 -2.2 -27.5 -51.3 -16.3  
Net earnings  -3.4 -2.2 -27.5 -51.3 -16.3  
Pre-tax profit without non-rec. items  -3.4 -2.2 -27.5 -51.3 -16.3  

 
See the entire income statement

Balance sheet (kDKK) 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Tangible assets total  0.0 0.0 0.0 0.0 0.0  
Shareholders equity total  0.8 -1.4 -19.0 -18.8 -35.1  
Interest-bearing liabilities  0.0 40.2 55.4 44.2 61.7  
Balance sheet total (assets)  42.5 42.8 41.3 43.2 42.0  

Net Debt  -1.2 38.7 55.4 42.3 61.0  
 
See the entire balance sheet

Volume 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  -3.4 -2.2 -27.5 -53.7 -18.9  
Gross profit growth  86.4% 34.2% -1,129.4% -95.4% 64.7%  
Employees  0 0 0 1 1  
Employee growth %  0.0% 0.0% 0.0% 0.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  43 43 41 43 42  
Balance sheet change%  -5.8% 0.6% -3.5% 4.6% -2.8%  
Added value  -3.4 -2.2 -27.5 -53.7 -18.9  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  0 0 0 0 0  

Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  -4.0 -5.0 -5.0 -5.0 -5.0  

Profitability 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  100.0% 100.0% 100.0% 100.0% 100.0%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  -7.8% -5.2% -52.6% -83.9% -23.5%  
ROI %  -135.3% -10.9% -57.5% -102.9% -30.8%  
ROE %  -137.2% -10.3% -65.5% -121.6% -38.3%  

Solidity 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Equity ratio %  1.9% -3.3% -31.5% -30.3% -45.5%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  36.4% -1,732.7% -201.4% -78.8% -322.2%  
Gearing %  0.0% -2,781.2% -292.2% -235.7% -175.9%  
Net interest  0 0 0 0 0  
Financing costs %  0.0% 0.0% 0.0% 0.2% 0.0%  

Liquidity 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Quick Ratio  0.0 0.0 0.0 0.0 0.0  
Current Ratio  0.0 0.0 0.0 0.0 0.0  
Cash and cash equivalent  1.2 1.5 0.0 1.9 0.7  

Capital use efficiency 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  -40.5 -42.7 -60.2 -60.0 -76.4  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Net sales / employee  0 0 0 0 0  
Added value / employee  0 0 0 -54 -19  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  0 0 0 -54 -19  
EBIT / employee  0 0 0 -54 -19  
Net earnings / employee  0 0 0 -51 -16